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Schistosomiasis remains a neglected tropical disease of major public health concern with
high levels of morbidity in various parts of the world. Although considerable efforts in
implementing mass drug administration programs utilizing praziquantel have been
deployed, schistosomiasis is still not contained. A vaccine may therefore be an
essential part of multifaceted prevention control efforts. In the 1990s, a joint United
Nations committee promoting parasite vaccines shortlisted promising candidates
including for schistosomiasis discussed below. After examining the complexity of
immune responses in human hosts infected with schistosomes, we review and discuss
the antigen design and preclinical and clinical development of the four leading vaccine
candidates: Sm-TSP-2 in Phase 1b/2b, Sm14 in Phase 2a/2b, Sm-p80 in Phase 1
preparation, and Sh28GST in Phase 3. Our assessment of currently leading vaccine
candidates revealed some methodological issues that preclude a fair comparison
between candidates and the rationale to advance in clinical development. These
include (1) variability in animal models - in particular non-human primate studies - and
predictive values of each for protection in humans; (2) lack of consensus on the
assessment of parasitological and immunological parameters; (3) absence of reliable
surrogate markers of protection; (4) lack of well-designed parasitological and
immunological natural history studies in the context of mass drug administration with
praziquantel. The controlled human infection model - while promising and unique -
requires validation against efficacy outcomes in endemic settings. Further research is
also needed on the impact of advanced adjuvants targeting specific parts of the innate
immune system that may induce potent, protective and durable immune responses with
the ultimate goal of achieving meaningful worm reduction.
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Disease Burden
Schistosomes are digenea trematodes within the clade of
platyhelminths. Human pathogenic species include Schistosoma
haematobium (Sh) and S. mansoni (Sm) occurring throughout
Africa and the Middle East. The former is also found in
Mediterranean Europe and the latter also in South America.
S. japonicum (Sj) and S. mekongi occur in Central, East and
South-East Asia (1–3). Schistosomiasis is a neglected tropical
disease (4) that is estimated to affect more than 240 million
people (5, 6). The 2016 Global Burden of Disease study suggested
that of all diseases assessed, schistosomiasis revealed the most
pronounced reduction in age-standardized years lived with
disability (YLD) between 2006 and 2016. Low infection
intensities with minimal clinical symptoms likely underestimate
the true burden of infected individuals leading to a hypothetical
correction of one egg-negative case for each egg-positive case and
an adjusted 400 and 600 million infected people globally (7, 8).
Initial infections occur in endemic settings with typical
transmission patterns among young children two years of age
with increasing infection intensities during the following 10 years
of life, peaking among young adolescents and decreasing during
adulthood. An estimated 60-80% schoolchildren and 20-40%
adults have persistent infections (9, 10). Sh-HIV co-infections,
especially among women suffering from genital mucosal
inflammation and ulceration, and Sm-Plasmodium spp. co-
infections are considered important contributors to the HIV and
malaria epidemics in Africa (11–14). Genital schistosomiasis
caused by Sh is a common gynecologic condition affecting an
estimated 40 million African women (15).
Parasite Pathogenicity
Definitive mammalian hosts acquire infection via skin
penetration during contact with fresh water infested with
infectious larval cercariae released from intermediate species-
specific snail hosts. Cercariae transform to juvenile schistosomes
or schistosomula before entering the vascular system, where they
migrate to their venous destination to mature and mate with
their sexual counterparts (16). Adult worms spend much of their
lives in copula and are capable of existing in immunocompetent
hosts for decades. The adult worms migrate to the mesenteric
venules of the intestine, i.e. Sm and Sj, or the venous plexus of the
bladder, i.e. Sh, where females residing in the gynaecophoric
canal of males produce hundreds of eggs daily that are
subsequently fertilized by males. Ova released via feces for Sm
and Sj or urine for Sh continue their lifecycle upon hatching in
fresh water as miracidia and multiplication by asexual replication
in snail hosts prior to transmission to definitive hosts.
Clinical disease in humans can be divided into acute and
chronic manifestations. Acute schistosomiasis is seen among
individuals without previous parasitic exposure and presents as
debilitating febrile illness at six to eight weeks post infection.
Chronic schistosomiasis is caused by inflammatory,
immunopathological host responses and organ damage due to
bleeding, scarring, and formation of granulomata and fibrosis
around eggs retained in tissues. Schistosomiasis clinical featuresFrontiers in Tropical Diseases | www.frontiersin.org 2are parasite species-dependent with intestinal, hepatic and
urinary pathology including malignancies, e.g., squamous cell
carcinomas in the bladder or sandy patches in the female genital
areas. It may affect other organs such as the central nervous
system through ectopic ova deposition, and lead to cognitive and
physical impairment - especially among children (7, 17, 18).
Schistosomes co-exist in immunocompetent hosts for decades
since they adapt, modulate, and evade cellular and humoral
immune defense mechanisms though with parasite species-
specific differences (9, 19). Their pivotal component for
switching from a young immune-sensitive to an adult
immune-refractory state is the tegument. It is a syncytial
matrix of fused cells overlaid by a lipoidal membranous bilayer
on the parasite outer surface, and essential for metabolic
processes, movement, and external interchange (16, 20–22).
Tegumental mechanisms to evade host defense components
include biophysical membrane adaptations with rapid
turnover, and alterations or masking of surface antigens and
immunomodulatory molecules (21).Host Immunity
Upon infection in humans, the immune system is confronted
with multiple moieties exposed during the various lifecycle
stages. Intact adult worms are impervious to immune attacks,
whereas the migrating skin- and especially lung-stage
schistosomula are targets of the cellular and humoral host
defense (9, 10, 23). Generally, hosts react in the following
general manner against schistosomal infections: (i) development
of age-dependent partial protective immunity to reinfection from
repeated adult worm death that releases immunologically active
molecules that induce adaptive immunity and (ii) initiation of
immunopathogenic and/or immunoregulatory mechanism
against parasitic antigens released from tissue-trapped ova (7,
17, 24, 25). In endemic settings, immune responses and disease
severity are influenced by multiple host factors, e.g., infection
intensity, cumulative treatment history, co-infection status,
genetics/genetic pre-disposition, and in utero transplacental and
postnatal oral antigen sensitization resulting in phenotypically
similar maternal and fetal responses (18, 26). Interestingly,
newborns of mothers with schistosomiasis have a pre-existing
anti-inflammatory T-helper 2 (Th2) response, IgM and/or IgE
anti-schistosome antibodies, and cord blood mononuclear cells
proliferating with anti-egg antibodies that induce altered
regulated responses to infections in these children (10, 18, 26).
The acute disease phase is characterized by pro-inflammatory
CD4+ T-helper 1 (Th1) or CD4+ Th1/T-helper 17 (Th17)
responses against migrating schistosomula with elevated
production of tumor necrosis factor alpha (TNF-a) and
interferon gamma (IFN-g) triggering innate phagocytic
antigen-presenting and epithelial cells to release larvicidal
molecules and other cytokines (18, 23, 27–30). For instance,
interleukin (IL)-17-activated neutrophils release neutrophilic
extracellular traps (NETs) to sequester schistosomula in the
bloodstream; IL-10-regulated IL-12 is essential for Th1-cell
differentiation (23, 31). Regulatory CD4+ T-cells (Treg)
provide an essential regulatory arm to stabilize the immuneAugust 2021 | Volume 2 | Article 719369
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receptors serve to limit the extent of immune-mediated
pathology during schistosomiasis (32). However, in Sh-infected
individuals Treg proportions rise significantly with increasing
infection in younger age groups. In contrast, Treg were
negatively correlated to infection intensity in older age groups
(32, 33). The chronic disease stage is defined by anti-
inflammatory CD4+ Th2 responses against egg epitopes with
antigen-presenting cells, members of the B7 superfamily, and
cytokines to downregulate the pro-inflammatory response (18).
IL-10, which has a role in T-cell regulation with IL-4, prevents
damages from Th1/Th2-mediated pathologies, and polarizes
Th1/Th2 responses to enhance resistance to pathogens, and
mitigate disease severity, thus improving host survival (27,
28, 34).
Extreme polarization is detrimental; the “happy valley”
hypothesis assumes best anti-parasite protection at either the
Th1- or the Th2-pole, and least protection at a well-mixed Th1/
Th2 balance where parasites seem “happiest” (27). IL-4 activates
phagocytic antigen-presenting and cytokine-producing
leukocytes and interacts with other cells presenting antigens in
endemic populations impacting vaccine efficacy and disease
susceptibility. Whether persistent schistosomiasis affects HIV
susceptibility or both agents interact is uncertain though viral
replication is higher when Th2-cells are present (18). Though
Th2-cells stimulate natural but only partial non-sterile resistance
to reinfection, they contribute long-term to disease chronicity
with granulomatous-fibrotic formations mediated by IL-4, IL-5
and IL-13, and STAT6 (signal transducer and activator of
transcription 6) pathways (32).
The B-cell contribution to parasite clearance and prevention
of disease severity is not well understood. IgE and IgA antibodies
confer protective immunity with resistance to reinfection, and
larval killing through antibody-dependent cell-mediated
cytotoxicity (ADCC) along with blood effector cells (27,
35–37). However, IgE antibodies develop slowly due to long-
lived schistosomes and antigen-exposure occurring only during
parasitic death. In contrast, IgG4, IgG2 and IgM against parasitic
carbohydrate epitopes are associated with susceptibility to
reinfection and disease severity along with mediators, e.g.,
IFN-g, Treg and IL-10, thus blocking protective antibodies (10,
35–37). Whether resistance to schistosomiasis is due to a
balanced mix of antibodies or to the presence or absence of a
particular antibody is unclear (35, 36). Vaccine-induced
hypersensitivity due to pre-existing IgE from past infections
are seen in other worms, e.g., for the Brazilian APS-based
hookworm vaccine in its Phase I trial (38, 39).
Prevention and Treatment
Preventive measures are multifaceted and include avoiding
contact with infectious water , improved access to
uncontaminated water, improved hygiene and sanitation,
elimination of intermediate freshwater snail hosts, and
provision of health education to high-risk populations,
especially in settings with dam construction, irrigation systems,
and internally/externally displaced persons (refugee camps) (40,
41). The drug of choice remains praziquantel (PZQ) (42). It isFrontiers in Tropical Diseases | www.frontiersin.org 3efficacious against adult worms by changing irreversibly the
tegumental permeability and stability but works poorly against
schistosome larva (9). Its full efficacy is impacted by host factors,
e.g., immune defense, infection intensity, exposure history, gut
microbiota, and physiological disposition and bioavailability,
and parasite factors, e.g., localization in bloodstream leading to
damage or recovery (9, 19, 20, 24, 42–45). Anti-worm rather than
anti-egg antibodies are reported to increase after PZQ treatment.
Initially, IgG4 leads to higher susceptibility to re-infection due to
IgE blocking but a decrease in susceptibility with regular
repeated treatment is seen due to decreased IgG4 levels (46,
47). The immunoregulatory role of PZQ is driven by the
promotion of CD4+ T-cells and differentiation of Type 1
regulatory cells to maintain immune hemostasis and effector
cytokine secretion - in particular IL-4, IL-5 and IL-10 (10, 45).
However, since PZQ cannot prevent reinfection, regular repeated
large-scale mass drug administration (MDA) is needed in
endemic settings, which requires large infrastructure and
financial investment. About 105 million people received
preventive treatment in 2019, though at least 237 million
people were in need (1, 44). The ability of PZQ to cure adult
worm infection and reduce egg excretion is important, but
concern over the potential of emerging resistance has arisen
because of its exclusive and extensive use over decades (7–9, 39,
42, 48, 49).ADVANCED VACCINE CANDIDATES
Given the limitations of MDA alone, a hypothesis is that
complementing a comprehensive approach with a safe and
effective vaccine would more likely be successful in
dramatically reducing the incidence of schistosomiasis (7).
Current research builds largely on the radiation-attenuated
cercarial vaccine considered as gold standard in terms of
immunological response in experimental models, but difficult
to be translated for human use. Single percutaneous
administration yields 60-70% protection against subsequent
challenge infection starting about two weeks post-
immunization and persisting for about 15 weeks in various
animal species and for several Schistosoma species (31, 50).
Preferred product characteristics for a schistosomiasis vaccine
have been proposed (7, 8). Since schistosomes do not replicate in
their definitive host, a prophylactic vaccine against
schistosomiasis should ultimately result in reduction of disease
manifestations as well as blocking transmission, thus reducing
force of transmission (7, 8). The goal is non-sterilizing immunity
with a long-term decline in tissue eggs and egg excretion -
preferably through killing of female worms - while preserving
concomitant natural immunity induced by non-pathogenic male
worms (8, 51–53). A candidate vaccine should be co-
administrable with PZQ in MDA programs and with existing
national vaccination programs. In the 1990s, a joint UNICEF,
UNDP, World Bank, WHO-TDR program promoting vaccines
against parasitic diseases shortlisted some promising candidates;
only few have progressed to pre-clinical and clinical stages: Sm-
TSP-2 which is in Phase 1b/2b, Sm14 in Phase 2a/2b, Sm-p80August 2021 | Volume 2 | Article 719369
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approval, and Sh28GST which has completed Phase 3 trials (51,
54, 55). We present findings from the literature and clinical trials
registered at https://clinicaltrials.gov. For each of the four leading
vaccine candidates, we discuss the antigen, and preclinical and
clinical studies as applicable. Details on antigens, formulations,
study designs and findings are summarized in Supplementary
Tables S1–S4.
S. mansoni Tetraspanin: Sm-TSP-2/Sm-
TSP-2/Al®
The characteristics of tetraspanin (TSP) are summarized in
Figure 1 (56–61); detailed pre-clinical and clinical
investigations of Sm-TSP-2 are presented in Supplementary
Table S1.
TSPs are scaffold proteins regulating the trafficking, functioning
of membrane proteins, cell-cell interactions, and tegumental
formation; they share a topology of an intracellular N- and C-
terminal loop, and extracellular loops EC1 and EC2 with species-
specific phylogenetic differences stimulating differential protection
(56–60). TSP’s species-specific genetic polymorphism - especially
within the EC2 external loop - and subclass diversity impact its host
range and suitability as a target of protective immunity in addition
to cross-species protection (62). Gene sequences of the EC2-domain
from Kenyan Sm male worms revealed the greatest degree of
polymorphism found in Schistosoma spp (58). The sub-
tegumental Sm-TSP-2 of newly transformed schistosomula is an
easy target of protective immunity and uniquely recognized by IgG1
and IgG3 antibodies from individuals with acquired resistance to
schistosomiasis compared to chronically-infected subjects. Krautz-
Peterson et al. showed that a limited number of dominant
conformational epitopes on five major tegumental surface
membrane proteins, i.e., Sm-TSP-2, Sm23, Sm29, SmLy6B and
SmLy6F, are primary targets of serum antibodies from mice, rats
and humans infected with Sm. However, neither infecting
schistosomula nor mature adult schistosomes are substantively
impacted by the robust circulating antibodies specific to these
antigens (62). By contrast, Th1 responses to these antigens can be
harmful to schistosomes and are responsible for the reduction in
parasite load following vaccination (63, 64).
Screening sera of individuals from endemic areas of the state
of Minas Gerais, Brazil revealed higher anti-TSP-2 IgG1 and
IgG3 antibodies among putatively resistant individuals, though
no anti-TSP-1 antibodies were found. However, among
chronically-infected individuals, all IgG subclasses and IgE
were detected against soluble egg and worm antigens (65).
Injection of mice with schistosomula after electroporation with
Sm-TSP-1 and Sm-TSP-2 dsRNAs resulted in 61% and 83%
reductions in the numbers of parasites recovered from the
mesenteric veins four weeks later when compared to dsRNA-
treated controls. These results imply that TSPs play important
structural roles impacting tegument development, maturation, or
stability (61).
TSP orthologs in Sh and Sj with >90% sequence homology
indicate potential cross-species protection (66, 67). Protection
based on subclass diversity with differential expression ofFrontiers in Tropical Diseases | www.frontiersin.org 4transcripts across the parasitic lifecycle stages and higher
expression in female than male worms was investigated within
Sj-TSP-2. Immunizing mice with Sj-TSP-2 subclass C or
recombinant Sj-TSP-2 subclasses A-G resulted in no protection
(56, 66); however, administering Sj-TSP-2 subclass E or D
adjuvanted with or without complete Freund’s adjuvant (CFA)
or incomplete Freund’s adjuvant (IFA) resulted in reductions of
54% hepatic and 69% fecal eggs, and 53% hepatic and 52% fecal
eggs, respectively (56, 66, 68). Strong total IgG (IgG1 and IgG2a)
antibody responses with weak IgA, IgE and IgM levels were
detected, indicating an overall marked Th1/Th2 response (65).
Variations in the Sj-TSP-2 EC2 sequence may alter the affinity
or avidity to hosts’ immune responses and stimulate different
levels of protective efficacy. Experiments in mice with Sm-TSP-2
encoding EC2 or Sm-TSP-2/5B chimera (hookworm vaccine
candidate) co-administered with CpG/alum reduced worm
burden by 25-27% and 54-58%, and liver eggs by 20-27% and
48-56%, respectively, and induced higher titers of total IgG, IgG1
and IgG2 antibodies in the Sm-TSP-2/5B group (65, 69).
Analysis of sera of chronically-infected individuals from Sm
and hookworm endemic Minas Gerais, Brazil, did not reveal
Sm-TSP-2-specific (and Na-APR-1/5B) IgE antibodies despite
high IgE titers to crude schistosome soluble egg antigen.
Additional pre-clinical experiments combining Sm-TSP-2
with Sm29 adjuvanted with CFA/ICA conferred increased
protective efficacy (63). Similar to the aforementioned studies,
individuals from endemic areas in Brazil showed higher IgG
against Sm-TSP-2/Sm29 in naturally-resistant individuals,
suggesting that a multivalent vaccine might be better
recognized by individuals with a resistant phenotype (63).
Murine experiments with Sm-TSP-2/Sm29 vaccination resulted
in higher reductions of worm burden and granulomata, with
elicitation of total IgG, IgG1 and IgG2a antibodies with IFN-g
and TNFa cytokine production across groups, and a Th1
response with increasing antibody titers following additional
booster immunizations (63). Mice immunized with DNA-
based Sm29, Sm-TSP-2, Sm29 N/C-terminus/Sm-TSP-2
chimera or Sm29+Sm-TSP-2 had worm reductions of 17-22%,
22%, 31-32% or 24-32% and decreases in hepatic granuloma of
28%, 30%, 37% and 26% respectively (70). High total IgG to N/C-
terminus/SmTSP-2 chimera and Sm29+rSm-TSP-2 along with
high production of IFN-g and TNF-a -indicative of a Th1-biased
profile - were detected following cercarial challenge. DNA-based
immunization resulted in a lower protection rate compared to
recombinant protein formulations. A chimeric Sm multi-epitope
(Sm14, Sm21.7, Sm23, Sm29, Smp80, Smcb, and Sm-tsp-2),
subunit vaccine formulated with a novel TLR4 agonist induced
humoral and cellular immune responses suggestive of its
potential as a prophylactic or therapeutic vaccine (71). Taken
together, these findings justified taking Sm-TSP-2 (made in
Pichia pastoris) forward in clinical trials.
Sm-TSP-2/Alhydrogel (Sm-TSP-2/Al®) with or without
Glucopyranosyl Lipid Adjuvant in an Aqueous Formulation
(“GLA-AF”) was first tested in a Phase 1 dose-escalation trial
among healthy adults from a Sm non-endemic area
(NCT02337855) (49, 72). The vaccine was well tolerated withAugust 2021 | Volume 2 | Article 719369
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related serious adverse events reported. The proportion of
vaccinees responding 14 days post vaccination was 30%, 50%,
and 89% for 10µg, 30µg and 100µg antigen doses, respectively,
suggesting a dose-dependent response. IgG antibodies peaked at
day 127 post vaccination in the 30mg and 100mg cohorts, but
were not detectable in the 10mg cohort, and decreased by day 293
across cohorts. Magnitude and longevity of responses to Sm-
TSP-2/Al® with GLA/AF (AP10-701) were assessed in a
subsequent dose-escalation Phase Ib trial in healthy adults
from a Sm endemic Brazilian setting (NCT03110757), but the
findings are yet to be published (73). Safety, immunogenicity,
efficacy and cross-species protection against Sh of Sm-TSP-2/
Al® with AP10-701 are being investigated in Phase I and Phase
IIb trials among healthy adults from a Sm endemic setting in
Uganda (NCT03910972) (74).
S. mansoni Fatty Acid-Binding
Protein: Sm14
The characteristics of FABP are provided in Figure 1 (75–79);
pre-clinical and clinical investigations of Sm14 are in
Supplementary Table S2.
FABPs are expressed in all parasitic life cycle stages. Cytoplasmic
FABPs allow schistosomes to acquire fatty acids and cholesterol
from the host due to a lack of schistosome oxygen-dependent
synthetic pathways essential for membrane formation, protein
anchoring, maturation, and egg production (75–79). Sm FABP
shares 91%, 45%, 39% and 49% sequence homology with FABPs ofFrontiers in Tropical Diseases | www.frontiersin.org 5Sj, Echinococcus granulosus, Fasciola hepatica, and Clonorchis
sinensis, respectively; phylogenetic proximity may suggest
potential for cross-species protection (80–83).
Sm14-vaccinated mice exhibited a 41% reduction in worms
compared to unvaccinated controls; immunizing outbred
rodents with Sm14 formulated with or without CFA reduced
Sm worms by 66%-89% and Fasciola hepatica metacercariae by
100% (84–87). Administering adjuvanted Sm14 to ungulates
resulted in high cross-species protection against Fasciola
hepatica parasites and liver damage due to T-lymphocyte
infiltration, with strong IgM and IgG responses (88–90)
suggesting Sm14 as a vaccine candidate with cross-species
potential (91, 92). Goats immunized with synthetic Sm14
adjuvanted with RIBI/Al(OH)3 developed cross-species cellular
responses and strong humoral protection also against Fasciola
hepatica with declines in liver and gallbladder worms of 46%,
and a reduction of gross liver damage of 55% due to low
infiltration of CD2+, CD4+ and CD8+ T lymphocytes (87–90).
Early murine experiments showed worm reductions ranging
from 20-67%, and strong Th1-predominant responses without
impacting granulomatous-fibrotic reactions (92–100). Further
rodents immunized with Sm14 with CFA or pRSET-His-rSm14,
showed 72% protection and prevention of parasite maturation
and hepatic tissue damage by 100% (79, 84–87, 101).
Naturally resistant individuals in endemic areas demonstrate
a Th1 immune response to Sm14. Assessment of cell-mediated
responses among subjects from endemic areas in Brazil using
synthetic multi-epitope peptides of Sm14 (1-18, 32-48, and 53-FIGURE 1 | Antigen characteristics of advanced schistosomiasis vaccine candidates which progressed to pre-clinical and clinical development (details in
Supplementary Tables S1–S4). Sm, Schistosoma mansoni; Sh, Schistosoma haematobium; TSP, tetraspanin; GST, glutathione S-transferase; cGMP, current
Good Manufacturing Practice; AP10-701, glucopyranosyl lipid A (aqueous formulation); GLA-SE, glucopyranosyl lipid A in stable emulsion (TLR4 agonist); CpG-ODN,
oligodeoxynucleotides with unmethylated CpG dinucleotides (TLR9 agonist).August 2021 | Volume 2 | Article 719369
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recognized by the majority of individuals tested and
preferentially by resistant patients compared to non-infected,
infected and susceptible subjects. A marked Th1 immune
response profile corresponded with decreased granulomatous
fibrotic pathology (99, 102–105). Mixtures of synthetic peptides
of Sm14 and paramyosin with CFA/IFA induced a Th1/Th2
immune response with noticeable reductions of worms,
intestinal eggs, and hepatic granuloma suggesting that multi-
epitope-based vaccines increase the frequency of responders in
genetically distinct populations. Multi-epitope and multi-valent
(Sm14 and Sm29) adjuvanted vaccine candidates elicited Th2-
dominant protection and a decline in granulomatous-fibrotic
pathologies in different animal models (102–105). Sm14 antigens
from different expression systems, e.g., Mycobacterium spp.,
Clostridium spp., and Salmonella spp., were of moderate
efficacy (101, 106–110). Subsequent optimization of expression
and fusion systems and adjuvant formulations elicited strong
total IgG and IgG subclass responses with induction of cells
positive for IFN-g, TNF-a and other cytokines associated with
reductions in worms, hepatic granuloma, and egg counts (92–
101, 106–110). Similarly, bivalent constructs (Sm14/Sm28 GST
expressed in Escherichia coli, Sm14/Sm29, and FSm14/29
adjuvanted with poly(I:C), administered in murine models
resulted in declines in adult worms, hepatic and intestinal eggs,
and hepatic granuloma size and frequency, and elicitation of Th1
immune responses (87, 103–106, 110).
Sm14 expressed in Pichia pastoris and adjuvanted with GLA
in a stable emulsion (GLA-SE) advanced into a safety and
immunogenicity Phase 1 clinical trial among healthy adults
from a non-endemic Brazilian area (NCT01154049) (111–113).
The vaccine given intramuscularly at weeks 0, 4 and 8 was safe
and well tolerated, and no vaccine-related serious adverse event
was reported. Sm14-specific total IgG and IgG1-4, were induced
from day 30 until day 90 together with Th-1 and Th-2 cytokines;
no IgE were detected suggestive of reduced risk of vaccine-
induced hypersensitivity. Safety and immunogenicity of Sm14/
GLA-SE were assessed in a Phase 2a trial among adults with
history of Sm and/or Sh infections from the hyperendemic
Senegal River Basin, Senegal (114). Adults received one dose of
PZQ three weeks prior to vaccination (NCT03041766) (113,
114). Preliminary results suggest that Sm14/GLA-SE was safe
and well tolerated and resulted in 92% seroconversion after the
second booster dose. Sm14-specific antibody titers were detected
up to 12 months after initial immunization (113). A Phase 2b 3-
arm self-contained open-label controlled randomized trial is
ongoing among healthy and Sm- and/or Sh-infected
schoolchildren from the Senegal River Basin receiving a single
dose of PZQ prior vaccination to further assess the safety and
immunogenicity of Sm14/GLA-SE (NCT03799510) (113, 115).
S. mansoni Large-Subunit Calpain:
Sm-p80/SchistoShield®
The characteristics of calpain are summarized in Figure 1 (116–
125); detailed pre-clinical results using Sm-p80 are in
Supplementary Table S3.Frontiers in Tropical Diseases | www.frontiersin.org 6Calpain is a proteolytic protein for membranous biosynthesis
consisting of a catalytic and a regulatory subunit. The large
subunit, Sm-p80, changes to a membrane-bound status through
calcium-activated auto-proteolysis by the small subunit (124,
125). It shows no immunological cross-reactivity with calpains in
vertebrates; Sm-p80 is expressed in all schistosome lifecycle
stages though with a 2.5-fold higher expression in females
compared to male adult worms, and plays a pivotal role in
membranous biosynthesis and turnover (116–123). Sm-p80
induced cross-species protection against Sh with reductions of
48% worms, and 66% and 63% hepatic and intestine eggs in
Syrian hamsters, respectively, and reductions of 25% worms, and
64% urinary bladder, 40% fecal and 53% urinary eggs in Papio
anubis baboons with robust immune responses indicative of
balanced Th1/Th17 immunity though slightly biased to a Th2
response (125, 126). Cross-species protection was also shown
against Sj using GLA-SE-adjuvanted Sm-p80, and against Sh
using a Sm-p80-VR1020 DNA prime and CpG-ODN-
adjuvanted protein boost approach with reductions of 47% of
worms and 5% of hepatic eggs in mice, and reductions of 27%
worms but no effects on hepatic, intestinal and urinary eggs in
hamsters, respectively, and a balanced Th1/Th2 immune
response (122, 126).
Sm-p80 expressed in baculovirus and adjuvanted with CFA
resulted in 67% worm reduction in immunized mice challenged
with Sm (124). Neither subcutaneous nor intranasal delivery of
recombinant vaccinia virus-expressed protein-based Sm-p80
decreased adult worms, while DNA immunization via gene
gun provided 60% protection with a Th1-based immune
response against cercarial challenge (127). Sm-p80 DNA
administered intramuscularly with IL-2 or IL-12 to mice at
weeks 0, 4 and 8 followed by cercarial challenge resulted in
57% and 45% decreases in adult worms, respectively. Total IgG,
IgG2a and IgG2b antibodies were enhanced in the presence of
either interleukin indicative of a Th1 response, but no IgA, IgE
and IgM antibodies were detected, which is a hallmark of Sm-p80
(52). The same DNA construct co-administered with the
granulocyte-macrophage colony-stimulating factor (GM-CSF)
or IL-4 conferred similar worm reductions of 44% and 42%
compared to IL-2 or IL-12, respectively; Sm-p80-DNA given
with GM-CSF or IL-4 resulted in the augmentation of both Th1
and Th2 responses, but no IgA, IgE and IgM antibodies (116).
Subcutaneous immunization of mice with Sm-p80 DNA alone or
adjuvanted with GM-CSF, IL-4, IL-12, or IL-2 followed by Sm
cercarial challenge confirmed protective effects with decreased
worm burden as in earlier experiments. Mouse splenocytes
showed high in vitro proliferation indicative of a protective
Th1 immune response (128). Increasing the frequency of DNA
boosts resulted in 59% and 84% decrease of worm and egg
burdens, respectively, with distinct total IgG, IgG1, IgG2a,
IgG2b, IgG3 titers mediated by IFN-g and IL-2 even without
added adjuvants (129).
Vaccinating mice in a Sm-p80 DNA prime and protein boost
versus Sm-p80 alone co-administered with Resiquimod (R848,
TLR7/8 agonist) resulted in 49% and 50% worm as well as 30%
and 16% egg reductions, respectively. In contrast, the sameAugust 2021 | Volume 2 | Article 719369
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administered with CpG-ODN conferred decreases of 57% and
70% in adult worms, and 71% (65% anti-fecundity) and 75%
(77% anti-fecundity) reduction in egg counts, respectively (30).
The use of R848 resulted in high titers of IgM, IgA, total IgG and
IgG1, IgG2a, IgG2b, and IgG3 together with pro-inflammatory
cytokines in addition to IL-15 and IL-16 indicating a Th1 type
immune response (130) - similar to the immune response seen in
the CpG-ODN experiment though titers were higher with Sm-
p80 alone. Both approaches elicited strong mixed Th1/Th17 and
Th2 biased cellular responses (30).
Papio anubis baboons which develop a schistosomiasis
syndrome similar to humans and are natural hosts for various
Schistosoma species were vaccinated intramuscularly with 500mg
Sm-p80 DNA alone or IL-2-adjuvanted followed by three boosts
at 4-week intervals (8, 131). Immunized animals exhibited a Th1
response with 21-34% complement-dependent killing of
schistosomula. A proof-of-concept study in non-human
primates assessed the safety and prophylactic anti-fecundity
potential of non-adjuvanted DNA immunization followed by a
subcutaneous challenge with 1,000 Sm cercariae. The vaccine was
well tolerated and showed 38% reduction in worms (30% males
and 14% females), 50% reduction of paired worms, 6% reduction
in immature worms, and 32% reduction hepatic and intestinal
eggs, and a mixed Th1/Th2 response with Th1 dominance (118,
132–134).
Sm-p80 DNA cloned in vector VR1020 administered to mice
resulted in a decrease in 47% adult worm and high total IgG and
IgG2b titers following cercarial challenge indicative of a Th1/
Th17 immune response (118). Baboons immunized with Sm-
p80-VR1020 showed similar reductions in adult worms of 46%,
and of hepatic and intestinal eggs of 28%, and a mixed Th1/Th2
response (133). The co-administration of Sm-p80-VR1020 or
Sm-p80 protein with alum in mice saw reductions of 61% and
55% adult worms and 23% and 21% eggs counts, respectively,
coupled with a robust Th1/Th2 response with strong IgM, total
IgG, IgG1, IgG2 and IgG3 levels, and upregulation of pro-/anti-
inflammatory cytokines affecting Th17 and Treg functions (134).
Immunization of non-human primates with Sm-p80-VR1020
followed by two boosts 4 weeks apart with Sm-p80 protein
adjuvanted with CpG-ODN or R848 resulted in adult worm
declines of 47% and 38% versus 58% and 52% with protein alone,
respectively. Total IgG, IgG1, IgG2 and IgA antibodies coupled
with IFN-g and IL-2 expression in peripheral blood mononuclear
cells, splenocytes and lymph node cells, but no IgG3 and IgG4
were elicited in either group, indicative of a mixed/balanced Th1/
Th17 and Th2 response (39).
Human correlate studies revealed Sm-p80 reactivity with
immunoglobulin G in human serum samples from
schistosome-infected individuals. In addition, a complete lack
of prevailing Sm-p80–specific immunoglobulin E in high-risk or
infected populations was observed, thus minimizing the risk of
hypersensitivity reaction following vaccination with Sm-p80 in
humans (39). This study provided the proof-of-concept to move
Sm-p80 forward into further translational development leading
to human clinical trials.Frontiers in Tropical Diseases | www.frontiersin.org 7In order to dissect the role(s) of antibodies in Sm-p80
mediated protection, pooled sera from mice immunized with
Sm-p80-DNA or purified IgG from baboons immunized with
Sm-p80-DNA were transferred intravenously into naïve mice,
respectively, prior to challenge with cercariae. Passive transfer of
sera or purified IgG antibodies from mice and baboons
vaccinated with Sm-p80 DNA into naïve mice with subsequent
cercarial challenge resulted in decreases in adult worms, hepatic
eggs and egg hatching from tissues, suggesting that antibodies
play a significant role in Sm-p80-mediated protection (135). Sera
from immunized baboons were able to kill a significant
proportion of schistosomula in a complement-dependent
manner (135, 136). Naïve versus antibody gene locus knockout
mice immunized with Sm-p80 with CpG-ODN showed
reductions of 63% and 18% adult worms, and 47% and 36%
eggs, respectively; this decrease in protection demonstrates that
antibodies in addition to complement are an essential
component -but not the only one - of Sm-p80-mediated
protection. Immunization of wild-type and complement-3-
deficient mice with Sm-p80 with CpG-ODN showed that
complement plays a minimal protective role in vitro though it
may impact the development of egg-induced pathology. Worms
were reduced by 53% and 34%, respectively, while 15 to 25-fold
lower levels of trapped hepatic and intestinal tissue eggs were
seen in complement-3-deficient than wild-type mice (119).
ADCC protection using lung lavage and lung cells was assessed
in mice vaccinated with Sm-p80 with CpG-ODN (137). High
levels of larvicidal killing and cellular attachments of
macrophages, lymphocytes, and endothelial cells activated by
cytokines were found suggesting that at least in mice lung cells
play pivotal roles in Sm-p80-mediated immunity to
schistosomiasis. Sm-p80-specific IgG antibodies were detected
up to 60 weeks in mice and 5-8 years in baboons, including
maternal co-protection through placental transfer, colostrum or
lactation after administration of Sm-p80 with GLA-SE and Sm-
p80-DNA with IL-2, respectively (137, 138).
Immunization of chronically infected baboons with Sm-p80
adjuvanted with GLA-SE resulted in declines of 36% adult
worms, 54% tissue eggs, and 33% fecal eggs; immunizing
baboons with a Sm-p80-VR1020 DNA prime and Sm-p80
protein boost adjuvanted with alum or CpG-ODN led to
reductions of 10% worms, 10% tissue eggs and 15% fecal eggs,
and of 23% worms, 57% tissue eggs and 13% fecal eggs,
respectively (139). Total IgG and IgM were detected in all
groups, but the expression of IgA and IgG subclasses, and
cytokines differed; balanced Th1/Th17 and weak Th2 profiles
were potent to kill established worms, and to reduce egg
retention and expulsion (133, 139, 140). Immunofluorescence
studies on Sm-p80 show it is highly expressed on eggs while still
in the uterus of females, which may suggest that eggs may be
damaged by Sm-p80-specific antibodies through tegument
permeation. Correspondingly, infected baboons immunized
with Sm-p80 with GLA-SE had a 68% reduction in liver eggs
with 86% decline in the hatching rate (141). Following
vaccination of baboons with Sm-p80 with GLA-SE, egg levels
were reduced in liver (91%), small intestine (87%), and largeAugust 2021 | Volume 2 | Article 719369
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miracidia decreased by 93% and 82%, respectively (123, 126).
The retention of some non-pathogenic male worms of stunted
growth and shorter life spans due to lack of pairing in the absence
of female worms may be of benefit in recurrent boosting of the
natural immunity and resistance to schistosomiasis. Livers had
soft, smooth texture with fewer, smaller granulomas and necrosis
surrounding trapped eggs compared to control animals (123).
Sm-p80-based vaccine efficacy was evaluated in a baboon
model of infection and disease. The efficacy study aimed to
replicate the scenario of implementing Sm-p80 in endemic
settings subsequent to drug treatment of infected individuals.
Sm-p80-based vaccination reduced hepatic- (38%), small
intestine- (72.2%) and large intestine-egg burdens (49.4%). Sm-
p80 also reduced hatching rates by 60.4%, 48.6%, and 82.3%,
respectively (142). Observed declines in egg maturation and
hatching rates were supported by immunofluorescence and
confocal microscopy revealing unique differences in Sm-p80
expression in worms of both sexes and matured eggs.
Immunizing baboons resulted in 64.5% reduction of the urine
schistosome circulating anodic antigen, a parameter that reflects
worm numbers and health status of infected hosts. Total IgG titers
were unchanged during trickle infection but increased following
PZQ treatment and vaccination. Transcriptomes of peripheral
blood mononuclear cells, and secondary lymphoid tissues among
vaccinated baboons exhibited induction, activation and
proliferation of innate and adaptive humoral and cellular
elements, including memory immune responses (142). Phase 1
clinical trials are proceeding now in US adults (first-in-human)
followed by dose-escalation among African adults with future age-
de-escalation to children with SchistoShield® (Sm-p80 expressed
in E. coli and adjuvanted using GLA-SE).
S. haematobium Glutathione
S-Transferase: Sh28GST (Bilharvax®)
The characteristics of GST are summarized in Figure 1 (143–
151); detailed pre-clinical and clinical studies of the candidate are
provided in Supplementary Table S4.
Comparative analyses on sera from exposed individuals
before and after PZQ treatment known for altering
schistosome-specific immune reactions qualitatively and
quantitatively were performed to identify and characterize
immunogenic Sh proteins (152). These studies show that GST
is involved in detoxification and antioxidant pathways (144,
151). The protein is expressed on the tegument and sub-
tegument of adult schistosomes of many species and plays a
pivotal role in modulating the host’s immune response during
infection. Inhibition of its enzymatic activities through
neutralizing antibodies following immunization may be
detrimental to the parasite. As key player of host-parasite
interactions 28GST is an attractive vaccine candidate (143–
151). It is a dimer of two very similar monomers, each having
N- and C-terminal domains (144). Comparisons of Sh28GST
and Sb28GST show that 75% of all residues are fully conserved
among Sm, Sj, Sh, and S. bovis (Sb), suggesting a close
evolutionary relationship (145, 151).Frontiers in Tropical Diseases | www.frontiersin.org 8Initial research revealed that the passive transfer of 28GST-
specific IgM antibodies with blocking effect of the enzymatic
activity of Sm28GST in rodents resulted in worm decline,
impairments in the female fecundity, and reduced egg viability
related to laying, hatching and tissue deposition, suggesting that
blocking effects of enzyme activities are detrimental to parasites
(153). Interestingly, though PZQ has no pharmacological effect
on the functional enzymatic activities of Sh28GST, its binding to
Sj26GST results in a steric inhibition and altered immune
responses and transport for large ligands. Whether
upregulation or mutagenesis of parasitic GST could confer
resistance to PZQ is debatable but may suggest the need for
additional anti-schistosomal drugs (144, 151, 152, 154, 155).
Early pre-clinical experiments of Sh-infected Papio anubis
baboons and Erythrocebus patas monkeys immunized with
Sm28GST followed by homologous Sm or heterologous Sh
challenge, and cattle vaccinated with Sm28GST with or
without muramyl-di-peptide (MDP) or Sb28GST with or
without MDP followed by Sh and S. mattheei challenge,
showed heterologous immunity and protection post challenge
with anti-fecundity and improved organ pathology. This suggests
Sm28GST may have potential as polyvalent cross-protective
vaccine candidate (145–148, 156, 157). In mice, Sh28GST
elicited stronger IgA, IgG and IgE antibody titers compared to
Sh-infected mice (158–160). Similar immune responses with
predominant IgA, IgG and IgE antibodies were detected
among infected humans from highly endemic Senegalese and
Kenyan settings. IgE was positively correlated with older, lightly-
infected subjects and negatively correlated with younger, highly-
infected Zimbabweans (158–164). Naturally Sh-exposed
Zimbabwean children from an endemic area demonstrated the
highest and lowest Th2-cytokines among children aged 4-9 and
10-12 years of age, respectively, prior to PZQ treatment, and the
highest Th1-/Th2-/Th17-cytokine levels among children aged 4-
9 years six weeks post PZQ treatment (146).
Experiments using different expression vectors, e.g.,
Bordetella pertussis, Mycobacterium bovis, Saccharomyces
cerevisiae, and Salmonella Typhimurium, and administration
routes (intranasal, intraperitoneal and oral), among rodent and
monkey models induced mixed Th1/Th2 responses with dose-
dependent IgG1, IgG2a, IgG2b and IgA antibodies, and ADCC
(148, 149, 164–167). Wild-caught Erythrocebus patas monkeys
immunized with Sh28GST with CFA/IFA but not Sh28GST with
Bacillus Calmette-Guérin adjuvant developed IgG and IgA titers
with homogeneous anti-pathology processes, such as acute
eosinic and chronic sclerotic inflammations, compared to
heterogeneous processes in the alternate cohort (148). Dose-
escalation toxicological assessments of Sh28GST adjuvanted with
alum induced transient local inflammatory reactions and no
clinical, anatomical or physiological modifications among
rodents (168).
An initial Phase 1a trial assessed the safety, tolerability and
immunogenicity of 100mg Sh28GST expressed in Saccharomyces
cerevisiae and adjuvanted with alum followed by two booster
doses on day 28 and 150 in healthy adult Caucasians 18-30 years
of age (NCT01512277). A dose-escalation open-label trial ofAugust 2021 | Volume 2 | Article 719369
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was performed (168, 169). The vaccine was safe and well
tolerated with only mild vaccine-related adverse events. Th2-
type Sh28GST antibodies were induced by additional booster
doses in a dose-independent manner. IgG1, IgG2 and IgG3
subclass antibodies, weak IgA and IgG4 titers, and no IgE
antibodies, as well as a Th-1/Th-2 cytokine expression
response, were detected. Inhibition of GST enzymatic activity
was seen among all vaccine recipients and enhanced with
additional doses coupled with the production of IgG1 and
IgG3 subclass antibodies (143, 146, 168, 170). A subsequent
Phase 1b trial in non-infected children 6-10 years of age (115)
from schistosomiasis endemic Saint-Louis, Senegal, confirmed
the vaccine safety and tolerability and the induction of high
antibody titers (115, 143, 170). Bilharvax® in combination with
PZQ treatment was also safe in infected adults and children
(171). These preliminary clinical findings led to the
implementation of an efficacy trial.
A randomized, placebo-controlled Phase 3 trial investigated the
safety, efficacy, long-term recurrences of clinical and parasitological
manifestations, and immunogenicity of Bilharvax® among Sh-
infected school children 6-9 years of age in the Saint-Louis region
of the Senegal River Basin, with high endemicity (>60%) (171, 172).
Subsequent to clearance of ongoing schistosomiasis infection with
two doses of PZQ prior and post immunization at week 44, children
were randomized to receive three subcutaneous injections of either
Bilharvax® or Alhydrogel® alone serving as control group at weeks
0, 4, and 8 followed by a booster dose at week 52, one year after the
first injection (168, 171, 172). The primary endpoint was efficacy,
evaluated as delay of recurrence of urinary schistosomiasis, and
defined by a microhematuria associated with at least one living Sh
egg from baseline to week 152. Bilharvax® combined with PZQ was
safe and well tolerated. No disease recurrence was observed among
vaccinees during a median follow-up period of 76 and 92 weeks and
76 weeks among the vaccine and the control groups, respectively.
However, at week 152, at least one recurrence of urinary
schistosomiasis without differences in morbidity and
parasitological manifestations assessed by ultrasonography was
experienced by 86% and 85% of recipients in each group.
Sh28GST-specific total IgG, IgG1, IgG2, IgG4 and modest IgE
antibodies were elevated in the vaccine group, but unexpectedly
IgG3 and IgA titers were absent in both groups. The immune
response generated inhibited the enzymatic activity of Sh28GST
preventing schistosomiasis pathology; ≥70% of sera in the vaccine
group compared to 8% in controls had antibodies. The absence of
specific IgG3 antibodies in the vaccine group, and the low IgA and
IgE levels might represent a key factor involved in the lack of efficacy
of the vaccine in this trial. Indeed, previous studies have shown
elevated Sh28GST IgG3, IgE, and IgA antibodies compared to IgG1
in association with acquired immunity against reinfection to urinary
schistosomiasis (173). Immuno-epidemiological studies in human
populations indicate that the presence of IgG3 antibodies correlates
with naturally acquired protective immunity against schistosomiasis
(174). A Phase 1 clinical trial conducted in healthy subjects (168)
revealed that Sh28GST induced IgG1 and high IgG3 titers, an effect
that was associated previously with reduced egg production andFrontiers in Tropical Diseases | www.frontiersin.org 9decreased urinary tract pathology among Sh-infected individuals.
Future trials should thus reassess Bilharvax® in the absence of PZQ,
and preferably in non-infected younger children utilizing another
pro-Th1 adjuvant.METHODOLOGICAL CONSIDERATIONS
Animal Models and Predictive Value of
Protection in Humans
Among the experiments presented within the scope of this review,
there are notable differences between the animal models, and
parasitological and immunological assessments used - in particular
for non-human primate challenge studies. These differences render
comparisons between vaccine candidates and experimental
outcomes difficult. For example, the Sh28GST candidate failed to
confer efficacy in Phase 3 trials in humans while protection was
demonstrated in the Erythrocebus patas monkey model, which in
this case showed no positive predictive value. How would the Papio
anubis baboons challenge model used for Sm-p80 compare to the
Erythrocebus patas monkey model in terms of species susceptibility,
cercarial challenge method, and immunogenicity assessment?
With the exception of a few antigens, the prophylactic efficacy
of the majority of schistosome vaccine candidates has been
evaluated only in the murine model which, inherently, appears
to have an apparent ceiling of 40-50% protection (175). It is
therefore advisable that while designing immunization regimens
for clinical trials, data generated in the murine model should be
used with caution. Baboons may serve as a useful bridge between
mouse and human studies (8).
It is also noteworthy that two out of three vaccines candidates
that progressed to advanced clinical development were not tested in
non-human primate challenge models. The Sm14 vaccine entering
into Phase 2 has not been tested in non-human primates so far. It is
not clear whether Sm14 will undergo a challenge model experiment
before entering an efficacy trial. Sm-TSP-2 vaccine was also not
tested in non-human primates and it does not appear that this is
being considered in preparation of a Phase 2b trial in Uganda.
Parasitological Assessments
Across the evaluation of different schistosomiasis vaccines, there
does not seem to be a general consensus about parameters to
assess and the methods of measurement for non-human primate
challenge experiments and efficacy trials in humans.
Parasitological post-challenge outcomes as primary efficacy
endpoints are also difficult to interpret. In efficacy trials, it is
assumed that egg output and hatching percentage would be a
surrogate of worm burden to assess efficacy endpoints. The
determination of worm burden is only possible in non-human
primate models after portal perfusion. However, fecal egg output
and/or circulating antigen levels are surrogate markers in
humans. The sensitivity of these surrogates, the correlation
between worm burden and egg output, and the validation of
these surrogates in humans need further research.
In addition, the duration of protection is unknown since all
baboons in the reported trials were sacrificed. In a challengeAugust 2021 | Volume 2 | Article 719369
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are still ~7% of active female worms producing eggs with little
pathogenicity (123). It remains unclear how this would change
after longer periods of observation or repeated exposure.
Immune Response Assessment
and PZQ Impact
Across the evaluation of the different vaccine candidates, there
does not seem to be consensus about the assessment of the
following parameters: immune responses, including which
variables to measure, and time points; in addition, consensus is
needed on the method of measurement for non-human primate
challenge experiments and efficacy trials in humans in terms of
assay validation, standardization of reagents, and repository.
As highlighted in the Krautz-Peterson’s study (62), using
conformationally-native immunogens may be important when
preparing antibodies for detection of schistosome tegumental
antigens under natural conditions, such as for in situ localization
or live worm staining.
PZQ may modulate transient and long-term immunological
effects, which in turn may augment or antagonize vaccine-induced
immune responses and skew towards a more pro-inflammatory
response (47, 146, 176). In Zhang’s challenge study (123), the Sm-
p80 vaccine exhibited potent prophylactic efficacy against
transmission of Sm infection and was associated with significantly
less egg-induced pathology compared to unvaccinated control
animals. Specifically, the vaccine resulted in a 93.5% reduction
female worms and impacted significantly the major clinical
manifestations of hepatic and intestinal schistosomiasis by reducing
the tissue egg-load by 90%. A 35-fold decrease in fecal egg excretion
in vaccinated animals combined with an 81.5% reduction of egg
hatching into the snail-infective stage (miracidia) demonstrates the
parasite transmission-blocking potential of the vaccine. Higher Sm-
p80 expression in female worms and Sm-p80-specific antibodies in
vaccinated baboons appear to play an important role in vaccine-
mediated protection. The immune correlates of protection are,
however, not known (potential Th1 response with IFN-g, IgG1 and
IgG3)?. It must be noted that Ahmad’s work in non-human primates
describes a mixed Th1-Th2 response without IgG3 antibodies. Little
was learnt on immune correlates of protection however. Cell-
mediated immune responses were not assessed.
Vaccination neither induces IgG4 nor a pro-inflammatory
response after PZQ treatment and cercarial challenge. However,
the reduction of worms and eggs after PZQ before challenge was
not assessed (142). A clearer picture of these parasitological and
immunological parameters might be generated from the
comparison of the following groups: group 1 chronic infection,
group 2 chronic infection receiving PZQ, group 3 chronic
infection receiving PZQ with subsequent cercarial challenge,
and group 4 chronic infection receiving PZQ followed by Sm-
p80 vaccination and cercarial challenge.
To better understand field conditions of prior infection with
schistosomes and post treatment with PZQ, baboons underwent
Sm cercariae trickle infections over five weeks allowing the
development of chronic disease and were treated subsequently
with PZQ. After initial infection and during chronic disease,
there was an increase in NK and NKT cells while the CD4:CD8Frontiers in Tropical Diseases | www.frontiersin.org 10T-cell ratio inverted from 2:1 to 1:2.5. The cytokine expression in
peripheral blood mononuclear cells after trickle infections was
polarized more towards a Th2 response with a gradual increase
in the Th1 profile in the chronic disease stage. Following PZQ
treatment, immune cell populations reverted back towards naïve
pre-treatment levels with the exception of an increase in B cells;
however, expression of Th1, Th2, and Th17 cytokines was
significantly increased. The implications of such findings for
vaccine studies in baboons and humans remain unclear (177).
Natural history studies in areas targeted for efficacy trials
seem essential, in particular in the context of PZQ MDA. Using
well-established Brazilian cohorts of putative resistant and
chronically-infected individuals stratified by the intensity of
their Sm infection, arrays for IgG subclass and IgE responses
were probed to these antigens to detect antibody signatures that
were reflective of protective vs. non-protective immune
responses. Moreover, probing for IgE responses allowed
identifying antigens that might induce potentially deleterious
hypersensitivity responses if used as subunit vaccines in endemic
populations. Using multi-dimensional cluster analysis, the
authors showed that putatively resistant individuals mounted a
distinct and robust IgG1 response to a small set of newly
discovered and well characterized surface tegument antigens
compared to chronically infected individuals who mounted
strong IgE and IgG4 responses to many antigens (178).
In another set of studies, Sm-infected individuals recruited from a
schistosomiasis endemic area in Uganda, were treated with PZQ and
followed up from five weeks to one-year post-treatment. Pre-
treatment and five weeks post-treatment IgE, IgG1 and IgG4 levels
against recombinant schistosomula antigens SmKK7, SmLy6A,
SmLy6B and SmTSP7 were measured. Being male was associated
with higher pre-treatment IgG1 levels to SmKK7, SmLy6a and Sm
adult worms. There was no consistent association between the
detectable five weeks post-treatment antibody responses against
schistosomula antigens and reinfection intensity one year after
PZQ treatment. Sm-infected individuals exhibited detectable
antibody responses to schistosomula antigens that were affected by
treatment. These findings indicate that schistosomula antigens
induce highly heterogeneous antibody responses following
treatment besides prior exposure as well as poly-parasitism and
other co-infections. Some antigens induce an immune response and
give rise to increased antibodies, while other antigens do not, and this
could have implications for vaccine development (47, 179). More
natural infection studies are needed to elucidate the immune
responses before and after PZQ administration in geographical
areas where vaccine efficacy trials are planned. Finally, although
the latest non-human primate studies published (123, 142) use
sophisticated immune assessments, the statistical analysis of
baboon immunological data may benefit from new tools such as
COMPASS, a computational framework for unbiased combinatorial
polyfunctionality analysis of antigen-specific T-cell subsets, used in
HIV vaccine trials (180).
Controlled Human Infection Model
Controlled human infection models (CHIM) are gaining
recognition as an approach to accelerating vaccine development,
for use in both non-endemic and endemic populations. CHIMAugust 2021 | Volume 2 | Article 719369
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vaccines for further trials and advance the understanding of
protective immunity. The Sm CHIM model developed in the
Netherlands (181) might be an important vaccine assessment
tool providing guidance without being a gatekeeper of clinical
efficacy trials. Because responses to infections and candidate
vaccines are likely to differ between endemic and non-endemic
settings, it has been proposed to establish a Sm-CHIM in Uganda
where also Sh is endemic (182). A first dose-escalating clinical
safety trial in 17 volunteers using male Sm cercariae, which do not
produce eggs and therefore do not cause lasting pathology, as a
challenge was recently conducted in Leiden, the Netherlands
(NCT02755324). The primary endpoints were adverse events and
infectivity. A dose-related increase in adverse events due to acute
schistosomiasis syndrome, occurred in nine of 17 volunteers.
Overall, five volunteers reported severe adverse events (SAEs).
Infection with 20 Sm cercariae led to SAEs in 18% of volunteers
and high infection rates. Worm-derived circulating anodic antigen,
the biomarker of the primary infection endpoint, peaked in 82% of
volunteers during 3 to 10 weeks post exposure. All volunteers
showed IgM and IgG1 seroconversion and worm-specific cytokine
production by CD4+ T cells. All volunteers were cured with PZQ
provided at 12 weeks after exposure (183).
This model is not validated and its positive and negative
predictive values of the efficacy outcome of vaccines in humans
remain unclear. Also, it does not reflect the situation of endemic
areas in terms of age of target population, repeated natural
exposure, and PZQ rollout. It remains unclear what
parasitological and immunological parameters would be
assessed with the exception of serum circulating anodic antigen.CONCLUSIONS
Schistosomiasis remains a neglected tropical disease of major
public health concern with high levels of morbidity globally.
Despite considerable efforts in MDA programs, schistosomiasis
is still not contained. A schistosomiasis vaccine may be a critical
component of a multifaceted prevention control approach. Four
major vaccine candidates have entered advanced pre-clinical and
clinical development, but only one reached Phase 3 in Africa and
failed to confer meaningful efficacy. Several other promising
candidates are in preclinical and early clinical development. This
assessment of current candidates revealed some methodological
issues that preempt a predictive comparison between leads.
These include variability in animal models, in particular, non-
human primate studies, and their predictive value of protection
in humans, lack of consensus on essential parasitological andFrontiers in Tropical Diseases | www.frontiersin.org 11immunological assessment parameters and of reliable surrogate
markers of protection, and the need for better designed
parasitological and immunological natural history studies in
the context of PZQ. Although the CHIM model is a great
initiative, it needs to be validated for its positive and negative
predictive values for vaccine efficacy in endemic settings and
should not be considered as a gatekeeper offield trials in humans.
More research is also needed to test new potential vaccine
antigens such as cholinesterases regulating the neurotransmission
of Schistosoma (184), or new tegumental proteins identified by
microarray and other modern technologies (178, 185–189), and
more potent adjuvants targeting specific parts of the innate
immune system to tailor a protective immune response for lead
schistosome vaccine candidates with the long-term aim to achieve
high levels of worm reduction and ultimately elimination of this
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